Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway

Carcinogenesis

Volumn 29, Issue 7, 2008, Pages 1319-1326

  Cheng, Wei ^a,b   Tseng, Chia Jen ^c,d   Lin, Tom T C ^b   Cheng, I ^e   Pan, Hung Wei ^f   Hsu, Hey Chi ^a,f   Lee, Yu May ^c,d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b KEELUNG HOSPITAL   (Taiwan)

^c INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYPICAN 3; MITOGEN ACTIVATED PROTEIN KINASE; PROLINE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL; CELL STRAIN; CELL STRAIN 3T3; CELL STRAIN HUH 7; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLYPICANS; HELA CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; MICE; NIH 3T3 CELLS; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 49349103711     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn091     Document Type: Article

References (54)

1. Befeler,A.S. et al. (2002) Hepatocellular carcinoma: Diagnosis and treatment. Gastroenterology, 122, 1609-1619.
2. Lodato,F. et al. (2006) Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J. Gastroenterol. 12, 7239-7249.
3. Thorgeirsson,S.S. et al. (2002) Molecular pathogenesis of human hepato-cellular carcinoma. Nat. Genet., 31, 339-346.
4. Hsu,H.C. et al. (1997) Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: Biological significance and temporospatial distribution. Cancer Res., 57 5179-5184.
5. Capurro,M.I. et al. (2005) Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res., 65, 6245-6254.
6. Lage,H. et al. (1998) Expression of the novel mitoxantrone resistance associated gene MXR7 in colorectal malignancies. Int. J. Clin. Pharmacol. Ther., 36, 58-60.
7. Hishinuma,M. et al. (2006) Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for alpha-fetoprotein-producing gastric carcinoma. Histopathology, 49, 479-486.
8. Toretsky,J.A. et al. (2001) Glypican-3 expression in Wilms tumor and hepatoblastoma. J. Pediatr. Hematol. Oncol., 23, 496-499.
9. Nakatsura,T. et al. (2004) Identification of glypican-3 as a novel tumor marker for melanoma. Clin. Cancer Res., 10, 6612-6621.
10. Zynger,D.L. et al. (2006) Glypican 3: A novel marker in testicular germ cell tumors. Am. J. Surg. Pathol., 30, 1570-1575.
11. Stadlmann,S. et al. (2007) Glypican-3 expression in primary and recurrent ovarian carcinomas. Int. J. Gynecol. Pathol., 26, 341-344.
12. Xiang,Y.Y. et al. (2001) Glypican-3 expression is silenced in human breast cancer. Oncogene, 20, 7408-7412.
13. Lin, H. et al. (1999) Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res., 59, 807-810.
14. Filmus,J. et al. (1995) Identification of a new membrane-bound heparan sulphate proteoglycan. Biochem. J., 311, 561-565(Pt 2).
15. Jackson,R.L. et al. (1991) Glycosaminoglycans: Molecular properties, protein interactions, and role in physiological processes. Physiol. Rev., 71, 481-539.
16. Lander,A.D. (1994) Targeting the glycosaminoglycan-binding sites on proteins. Chem. Biol., 1, 73-78.
17. Lin,X., et al. (1999) Heparan sulfate proteoglycans are essential for FGF receptor signaling during Drosophila embryonic development. Development, 126, 3715-3723.
18. LaRochelle,W.J. et al. (1999) Heparan sulfate proteoglycan modulates keratinocyte growth factor signaling through interaction with both ligand and receptor. Biochemistry, 38, 1765-1771.
19. Pilia,G. et al. (1996) Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat. Genet., 12 241-247.
20. Xu,Y. et al. (1998) Developmental regulation of the soluble form of insulin-like growth factor-II/mannose 6-phosphate receptor in human serum and amniotic fluid. J. Clin. Endocrinol. Metab., 83, 437-442.
21. Pietrzkowski,Z. et al. (1993) Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res., 53, 1102-1106.
22. Baserga,R. (1994) Oncogenes and the strategy of growth factors. Cell 79, 927-930.
23. Resnicoff,M. et al. (1995) The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res., 55, 2463-2469.
24. Kaleko,M. et al. (1990) Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol. Cell. Biol., 10, 464-473.
25. Resnicoff,M. et al. (1994) Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res. 54, 2218-2222.
26. Scharf,J.G. et al. (2001) The IGF axis and hepatocarcinogenesis. Mol. Pathol., 54, 138-144.
27. Cariani,E. et al. (1988) Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res., 48, 6844-6849.
28. Nardone,G. et al. (1996) Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatology, 23, 1304-1312.
29. Scharf,J.G. et al. (2000) Analysis of the IGF axis in preneoplastic hepatic foci and hepatocellular neoplasms developing after low-number pancreatic islet transplantation into the livers of streptozotocin diabetic rats. Lab. Invest., 80, 1399-1411.
30. Tanaka,S. et al. (1997) Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology, 26, 598-604.
31. Nishiyama,M. et al. (1992) Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun., 183, 280-285.
32. Lin, Y.M. et al. (1982) [A new human hepatoma cell line: establishment and characterization]. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi, 15, 193-201.
33. Nakabayashi,H. et al. (1982) Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res., 42, 3858-3863.
34. De Cat,B. et al. (2003) Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. J. Cell Biol., 163, 625-635.
35. Vecchione,A. et al. (2003) The Grb10/Nedd4 complex regulates ligand-induced ubiquitination and stability of the insulin-like growth factor I receptor. Mol. Cell. Biol., 23, 3363-3372.
36. Ruddon,R.W. (1995) Cancer Biology. Oxford University Press, Inc.
37. Liu,H.S. et al. (1999) Is green fluorescent protein toxic to the living cells? Biochem. Biophys. Res. Commun., 260, 712-717.
38. Arbuthnot,P.B. et al. (1996) In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum. Gene Ther., 7, 1503-1514.
39. Abdallah,B.M. (2006) Osteoblast differentiation of NIII3T3 fibroblasts is associated with changes in the IGF-I/IGFBP expression pattern. Cell. Mol. Biol. Lett., 11, 461-474.
40. Hsu,H.C. et al. (1993) Expression of p53 gene in 184 unifocal hepatocellular carcinomas: Association with tumor growth and invasiveness. Cancer Res., 53, 4691-4694.
41. Hsu,H.C. et al. (2000) Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am. J. Pathol., 157, 763-770.
42. Kitisin,K. et al. (2007) Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene, 26, 7103-7110.
43. Zhang,X. et al. (1994) Deletions of chromosome 13q, Mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res., 54, 4177-4182.
44. Hsu,H.C. et al. (1994) Mutations of p53 gene in hepatocellular carcinoma (HCC) correlate with tumor progression and patient prognosis: a study of 138 patients with unifocal HCC. Int. J. Oncol., 4 1341-1347.
45. Giles,R.H. et al. (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta, 1653, 1-24.
46. Guan,X. et al. (2004) Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells. Thromb. Haemost., 92, 403-412.
47. Caro,J.F. et al. (1988) Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J. Clin. Invest., 81, 976-981.
48. Scharf,J.G. et al. (1998) Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC). Carcinogenesis, 19, 2121-2128.
49. Su,Q. et al. (1994) Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: Its relationship with hepatitis B virus antigen expression. Hepatology, 20, 788-799.
50. Werner,H. et al. (1996) The role of the insulin-like growth factor system in human cancer. Adv. Cancer Res., 68, 183-223.
51. Kim,H.J. et al. (2004) IGF-II-mediated COX-2 gene expression in human keratinocytes through extracellular signal-regulated kinase pathway. J. Invest. Dermatol., 123, 547-555.
52. Sciacca,L. et al. (2002) In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene, 21, 8240-8250.
53. Ito,Y. et al. (1998) Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology. 27, 951-958.
54. Song,H.H. et al. (2005) The loss of glypican-3 induces-alterations in Wnt signaling. J. Biol. Chem., 280, 2116-2125.